Skip to main content

Advertisement

Log in

Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

This is the second part of a two-part review on pheochromocytoma and paragangliomas (PPGLs). In this part, perioperative management, including preoperative preparation, intraoperative, and postoperative interventions are reviewed. Current data on outcomes following resection are presented, including outcomes after cortical-sparing adrenalectomy for bilateral adrenal disease. In addition, pathological features of malignancy, surveillance considerations, and the management of advanced disease are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Goldstein RE, O'Neill JA, Jr., Holcomb GW, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755–64 (discussion 764–756).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Kinney MA, Warner ME, van Heerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg. 2000;91(5):1118–1123.

    CAS  PubMed  Google Scholar 

  3. Kercher KW, Novitsky YW, Park A, Matthews BD, Litwin DE, Heniford BT. Laparoscopic curative resection of pheochromocytomas. Ann Surg. 2005;241(6):919–26 (discussion 926–918).

    PubMed  PubMed Central  Google Scholar 

  4. Steinsapir J, Carr AA, Prisant LM, Bransome ED, Jr. Metyrosine and pheochromocytoma. Arch Intern Med. 1997;157(8):901–906.

    CAS  PubMed  Google Scholar 

  5. Wachtel H, Kennedy EH, Zaheer S, et al. Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Ann Surg Oncol. 2015;22 Suppl 3:S646–54.

    PubMed  Google Scholar 

  6. van der Zee PA, de Boer A. Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin. Neth J Med. 2014;72(4):190–201.

    PubMed  Google Scholar 

  7. Randle RW, Balentine CJ, Pitt SC, Schneider DF, Sippel RS. Selective versus non-selective alpha-blockade prior to laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol. 2017;24(1):244–250.

    PubMed  Google Scholar 

  8. Buitenwerf E, Osinga TE, Timmers H, et al. Efficacy of alpha-blockers on hemodynamic control during pheochromocytoma resection—a randomized controlled trial. J Clin Endocrinol Metab. 2019.

  9. Kiernan CM, Solorzano CC. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. Surg Oncol Clin N Am. 2016;25(1):119–138.

    PubMed  Google Scholar 

  10. Witteles RM, Kaplan EL, Roizen MF. Safe and cost-effective preoperative preparation of patients with pheochromocytoma. Anesth Analg. 2000;91(2):302–304.

    CAS  PubMed  Google Scholar 

  11. Kalra JK, Jain V, Bagga R, et al. Pheochromocytoma associated with pregnancy. J Obstet Gynaecol Res. 2003;29(5):305–8.

    PubMed  Google Scholar 

  12. Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. Eur J Endocrinol. 2012;166(2):143–50.

    CAS  PubMed  Google Scholar 

  13. James MF, Cronje L. Pheochromocytoma crisis: the use of magnesium sulfate. Anesth Analg. 2004;99(3):680–6 (table of contents).

    PubMed  Google Scholar 

  14. Ahlawat SK, Jain S, Kumari S, Varma S, Sharma BK. Pheochromocytoma associated with pregnancy: case report and review of the literature. Obstet Gynecol Surv. 1999;54(11):728–37.

    CAS  PubMed  Google Scholar 

  15. Dahia PL, Hayashida CY, Strunz C, Abelin N, Toledo SP. Low cord blood levels of catecholamine from a newborn of a pheochromocytoma patient. Eur J Endocrinol. 1994;130(3):217–9.

    CAS  PubMed  Google Scholar 

  16. van der Weerd K, van Noord C, Loeve M, et al. Endocrinology in pregnancy: Pheochromocytoma in pregnancy: case series and review of literature. Eur J Endocrinol. 2017;177(2):R49–58.

    PubMed  Google Scholar 

  17. Kiernan CM, Du L, Chen X, et al. Predictors of hemodynamic instability during surgery for pheochromocytoma. Ann Surg Oncol. 2014;21(12):3865–71.

    PubMed  PubMed Central  Google Scholar 

  18. Livingstone M, Duttchen K, Thompson J, et al. Hemodynamic stability during pheochromocytoma resection: lessons learned over the last two decades. Ann Surg Oncol. 2015;22(13):4175–80.

    PubMed  Google Scholar 

  19. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.

    CAS  PubMed  Google Scholar 

  20. Hauch A, Al-Qurayshi Z, Kandil E. Factors associated with higher risk of complications after adrenal surgery. Ann Surg Oncol. 2015;22(1):103–10.

    PubMed  Google Scholar 

  21. Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144(11):1060–7.

    PubMed  Google Scholar 

  22. Anderson KL, Jr., Thomas SM, Adam MA, et al. Each procedure matters: threshold for surgeon volume to minimize complications and decrease cost associated with adrenalectomy. Surgery. 2018;163(1):157–64.

    PubMed  Google Scholar 

  23. Lindeman B, Hashimoto DA, Bababekov YJ, et al. Fifteen years of adrenalectomies: impact of specialty training and operative volume. Surgery. 2018;163(1):150–6.

    PubMed  Google Scholar 

  24. Walz MK, Alesina PF, Wenger FA, et al. Posterior retroperitoneoscopic adrenalectomy—results of 560 procedures in 520 patients. Surgery. 2006;140(6):943–8 (discussion 948–950).

    PubMed  Google Scholar 

  25. Perrier ND, Kennamer DL, Bao R, et al. Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg. 2008;248(4):666–74.

    PubMed  Google Scholar 

  26. Dickson PV, Alex GC, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2011;150(3):452–8.

    PubMed  Google Scholar 

  27. Carr AA, Wang TS. Minimally Invasive Adrenalectomy. Surg Oncol Clin N Am. 2016;25(1):139–52.

    PubMed  Google Scholar 

  28. Agcaoglu O, Sahin DA, Siperstein A, Berber E. Selection algorithm for posterior versus lateral approach in laparoscopic adrenalectomy. Surgery. 2012;151(5):731–5.

    PubMed  Google Scholar 

  29. Lee CR, Walz MK, Park S, et al. A comparative study of the transperitoneal and posterior retroperitoneal approaches for laparoscopic adrenalectomy for adrenal tumors. Ann Surg Oncol. 2012;19(8):2629–34.

    PubMed  Google Scholar 

  30. Mazeh H, Froyshteter AB, Wang TS, et al. Is previous same quadrant surgery a contraindication to laparoscopic adrenalectomy? Surgery. 2012;152(6):1211–7.

    PubMed  Google Scholar 

  31. Walz MK, Iova LD, Deimel J, et al. Minimally invasive surgery (MIS) in children and adolescents with pheochromocytomas and retroperitoneal paragangliomas: experiences in 42 patients. World J Surg. 2018;42(4):1024–30.

    PubMed  Google Scholar 

  32. Taskin HE, Berber E. Robotic adrenalectomy. J Surg Oncol. 2012;106(5):622–5.

    PubMed  Google Scholar 

  33. Aliyev S, Karabulut K, Agcaoglu O, et al. Robotic versus laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol. 2013;20(13):4190–4.

    PubMed  Google Scholar 

  34. Economopoulos KP, Mylonas KS, Stamou AA, et al. Laparoscopic versus robotic adrenalectomy: a comprehensive meta-analysis. Int J Surg. 2017;38:95–104.

    PubMed  Google Scholar 

  35. Feng Z, Feng MP, Levine JW, Solorzano CC. Robotic retroperitoneoscopic adrenalectomy: useful modifications of the described posterior approach. J Robot Surg. 2017;11(4):409–14.

    PubMed  Google Scholar 

  36. Feng Z, Feng MP, Feng DP, Rice MJ, Solorzano CC. A cost-conscious approach to robotic adrenalectomy. J Robot Surg. 2018;12(4):607–11.

    PubMed  Google Scholar 

  37. Nockel P, El Lakis M, Gaitanidis A, et al. Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery. 2018;163(1):191–6.

    PubMed  Google Scholar 

  38. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery. 1996;120(6):1064–70 (discussion 1070–1061).

    CAS  PubMed  Google Scholar 

  39. Grubbs EG, Rich TA, Ng C, et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg. 2013;216(2):280–9.

    PubMed  Google Scholar 

  40. Hull CJ. Phaeochromocytoma. Diagnosis, preoperative preparation and anaesthetic management. Br J Anaesth. 1986;58(12):1453–68.

    CAS  PubMed  Google Scholar 

  41. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011;13(11):843–7.

    CAS  Google Scholar 

  42. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665–75.

    PubMed  Google Scholar 

  43. Hamaji M. Pancreatic alpha- and beta-cell function in pheochromocytoma. J Clin Endocrinol Metab. 1979;49(3):322–5.

    CAS  PubMed  Google Scholar 

  44. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens. 2003;21(9):1703–7.

    PubMed  Google Scholar 

  45. Chen Y, Hodin RA, Pandolfi C, Ruan DT, McKenzie TJ. Hypoglycemia after resection of pheochromocytoma. Surgery. 2014;156(6):1404–8 (discussion 1408–1409).

    PubMed  Google Scholar 

  46. Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg. 1990;14(3):317–24.

    CAS  PubMed  Google Scholar 

  47. Wiesner TD, Bluher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. J Clin Endocrinol Metab. 2003;88(8):3632–36.

    CAS  PubMed  Google Scholar 

  48. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86(4):1480–6.

    CAS  PubMed  Google Scholar 

  49. Graham JB. Pheochromocytoma and hypertension; an analysis of 207 cases. Int Abstr Surg. 1951;92(2):105–21.

    CAS  PubMed  Google Scholar 

  50. Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel–Lindau syndrome after at least 5 years of followup. J Urol. 2010;184(5):1855–9.

    PubMed  PubMed Central  Google Scholar 

  51. Asari R, Scheuba C, Kaczirek K, Niederle B. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg. 2006;141(12):1199–205 (discussion 1205).

    CAS  PubMed  Google Scholar 

  52. Castinetti F, Qi XP, Walz MK, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 2014;15(6):648–55.

    PubMed  Google Scholar 

  53. Stolk RF, Bakx C, Mulder J, Timmers HJ, Lenders JW. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab. 2013;98(3):1100–6.

    CAS  PubMed  Google Scholar 

  54. Timmers HJ, Brouwers FM, Hermus AR, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer. 2008;15(4):1127–33.

    CAS  PubMed  Google Scholar 

  55. Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005;258(1):55–66.

    CAS  PubMed  Google Scholar 

  56. Beninato T, Kluijfhout WP, Drake FT, et al. Resection of pheochromocytoma improves diabetes mellitus in the majority of patients. Ann Surg Oncol. 2017;24(5):1208–13.

    PubMed  Google Scholar 

  57. Schovanek J, Martucci V, Wesley R, et al. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. BMC Cancer. 2014;14:523.

    PubMed  PubMed Central  Google Scholar 

  58. van Heerden JA, Roland CF, Carney JA, Sheps SG, Grant CS. Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s). World J Surg. 1990;14(3):325–9.

    PubMed  Google Scholar 

  59. Pruszczyk P, Januszewicz W, Feltynowski T, et al. Long term follow-up after surgical removal of pheochromocytoma—observations in 61 patients. Clin Exp Hypertens A. 1991;13(6–7):1179–94.

    CAS  PubMed  Google Scholar 

  60. Favia G, Lumachi F, Polistina F, D'Amico DF. Pheochromocytoma, a rare cause of hypertension: long-term follow-up of 55 surgically treated patients. World J Surg. 1998;22(7):689–93 (discussion 694).

    CAS  PubMed  Google Scholar 

  61. Hamidi O, Young WF, Jr., Iniguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296–305.

    PubMed  PubMed Central  Google Scholar 

  62. Dhir M, Li W, Hogg ME, et al. Clinical predictors of malignancy in patients with pheochromocytoma and paraganglioma. Ann Surg Oncol. 2017;24(12):3624–630.

    PubMed  Google Scholar 

  63. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63(17):5615–21.

    CAS  PubMed  Google Scholar 

  64. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943–51.

    CAS  PubMed  Google Scholar 

  65. Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92(10):3822–28.

    CAS  PubMed  Google Scholar 

  66. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551–66.

    PubMed  Google Scholar 

  67. Strong VE, Kennedy T, Al-Ahmadie H, et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery. 2008;143(6):759–68.

    PubMed  Google Scholar 

  68. Wu D, Tischler AS, Lloyd RV, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009;33(4):599–608.

    PubMed  Google Scholar 

  69. Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, Version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702.

    CAS  PubMed  Google Scholar 

  70. Plouin PF, Amar L, Dekkers OM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1–10.

    CAS  PubMed  Google Scholar 

  71. Amar L, Lussey-Lepoutre C, Lenders JW, Djadi-Prat J, Plouin PF, Steichen O. Management of endocrine disease: recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(4):R135–145.

    CAS  PubMed  Google Scholar 

  72. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60(12):1486–99.

    CAS  PubMed  Google Scholar 

  73. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20(11):648–658.

    CAS  PubMed  Google Scholar 

  74. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Nastos K, Cheung VTF, Toumpanakis C, et al. Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol. 2017;115(4):425–34.

    CAS  PubMed  Google Scholar 

  76. Ellis RJ, Patel D, Prodanov T, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg. 2013;217(3):489–96.

    PubMed  PubMed Central  Google Scholar 

  77. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109(4):267–73.

    CAS  PubMed  Google Scholar 

  78. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4(2):103–10.

    CAS  PubMed  Google Scholar 

  79. Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040–50.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

This manuscript was reviewed by the SSO Endocrine and Head and Neck Disease Site Working Group, and all members expressed support for its publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dhaval Patel MD.

Ethics declarations

Disclosures

Dr. Yang’s research is supported by the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (K08HL145139).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, D., Phay, J.E., Yen, T.W.F. et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine and Head and Neck Disease Site Working Group, Part 2 of 2: Perioperative Management and Outcomes of Pheochromocytoma and Paraganglioma. Ann Surg Oncol 27, 1338–1347 (2020). https://doi.org/10.1245/s10434-020-08221-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08221-2

Navigation